Clinical trials: SIADH
SIAD - Syndrome of Inappropriate Antidiuresis
Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction
Hyponatremia due to SIAD is frequently insufficiently corrected by fluid restriction alone, which remains the first-line therapy but is often poorly tolerated. Urea supplementation is recommended as second-line therapy.
- Trial name
- UREA-BIVA (NCT07528365)
- Testing
- urea
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Turin, Italy
Euvolemic Hyponatremia
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
The purpose of this study is to evaluate the safety and tolerability of oral lixivaptan capsules in subjects with Euvolemic Hyponatremia.
- Trial name
- NCT00876798
- Testing
- Lixivaptan
- Where
- 90 sites in United States, Belgium and 6 more
- Volunteers
- 206 people
- Sponsor
- CardioKine Inc.
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
Tolvaptan Versus Fluid Restriction in SIADH
Context. The relevance of hyponatremia has been acknowledged by guidelines from the United States of America (2013) and Europe (2014). However, treatment recommendations differ due to limited evidence. Objective.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Pituitary
- Trial name
- NCT04119206
- Volunteers
- 334 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Hyponatremia, SIADH
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Hyponatremia is the most common electrolyte derangement occurring in hospitalized patients. It is usually classified as hypovolemic, euvolemic or hypervolemic.
- Conditions
- Hyponatremia, SIADH, Liver Failure, Kidney Failure
- Trial name
- EMPOWER (NCT04447911)
- Testing
- Empagliflozin 25 MG
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 113 people
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
This observational, prospective, non-interventional study will include cancer patients who need a treatment for hyponatraemia secondary to SIADH.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Cancer
- Trial name
- ASSERT (NCT02573077)
- Where
- 20 sites in Italy
- Volunteers
- 69 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Inappropriate ADH Syndrome, Hyponatremia
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
To assess the efficacy of SR121463B in correcting hyponatremia in patients with syndrome of inappropriate antidiuretic secretion (SIADH).To assess the long-term efficacy of SR121463B in maintaining normal levels of serum sodium…
- Trial name
- SIADH (NCT00264927)
- Testing
- SR121463B
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 77 people
- Sponsor
- Sanofi
Inappropriate ADH Syndrome, Hyponatremia
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
To determine the long-term safety and tolerability of SR121463B in patients with syndrome of inappropriate antidiuretic secretion (SIADH).
- Trial name
- SIADH Safety (NCT00264914)
- Testing
- SR121463B
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 57 people
- Sponsor
- Sanofi
Syndrome of Inappropriate Antidiuresis (SIAD)
Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients With SIAD
This study aims to investigate whether a 7-day dietary high protein supplementation of 90 grams per day increases plasma sodium levels in hyponatremic patients with chronic SIAD.
- Trial name
- TREASURE (NCT04987385)
- Testing
- Protein supplementation, Oral urea
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia, SIADH
The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia
The aim of this study is to identify factors associated with hyponatremia among patients hospitalized in the internal medicine ward. Consequtive patients hospitalized because of hyponatremia will be recruited.
- Trial name
- 0597-10-HMO (NCT01509170)
- Where
- 2 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed.
- Trial name
- ALGA (NCT02548845)
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
This is a retrospective chart review non-interventional study designed to collect real world data on the use and outcomes of tolvaptan for the treatment of patients with hyponatraemia secondary to syndrome of inappropriate…
- Trial name
- SAMPLE (NCT02545101)
- Where
- 7 sites in Germany, Spain
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Hyponatremia
Study of Ascending Levels of Tolvaptan in Hyponatremia
The purpose of this study was to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this…
- Trial name
- SALT2 (NCT00201994)
- Testing
- Tolvaptan
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hyponatremia
Subclassification of the Syndrome of Inappropriate ADH Secretion
The aim of this study is to evaluate the different types of osmotic dysregulation in patients with Syndrome of Inappropriate ADH (SIADH) and, hence, to analyze the pathophysiology of SIADH.
- Trial name
- NCT01341665
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wuerzburg
Pituitary Adenoma
Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis
Water imbalance and consecutive electrolyte disturbances are common in the postoperative course of neurosurgical patients after pituitary surgery.
- Trial name
- NCT01465672
- Where
- 2 sites in Switzerland
- Volunteers
- 125 people
- Sponsor
- University Hospital, Basel, Switzerland
Inappropriate ADH Syndrome
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.
- Trial name
- DIVE (NCT02729766)
- Testing
- Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia, Inappropriate ADH Syndrome
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH.
- Trial name
- AQUARIST1 (NCT00728091)
- Testing
- Satavaptan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sanofi
Intravenous Fluids, Fluid and Electrolyte Imbalance
SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients
Intravenous fluids (IVF) are used in hospitalized patients to replenish the fluid and electrolyte losses of patients who cannot take adequate hydration by mouth or through their gut.
- Conditions
- Intravenous Fluids, Fluid and Electrolyte Imbalance, ADH Inappropriate
- Trial name
- SOFI (NCT03924674)
- Testing
- Education, clinical decision support tools
- Where
- 89 sites in United States
- Volunteers
- 106 people
- Sponsor
- Seattle Children's Hospital
Hyponatremia
Tolvaptan for In-hospital Hyponatremia
Hyponatremia is a common electrolyte disorder encountered in hospitalized patients. A preliminary, observational, feasibility analysis finalized to assess retrospectively the incidence of hyponatremia (Serum sodium < 135 mEq/L)…
- Trial name
- INSERT (NCT01386372)
- Testing
- Tolvaptan, Standard therapy
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Traumatic Brain Injury
Prevalence, Severity, Risk Factors, and Prognostic Value of Hyponatremia in Patients With Traumatic Brain Injury
Hyponatremia (HN) is the most common electrolytic disorder in the traumatic brain injury (TBI) population, found in 17 to 51% of patients according to the series.
- Trial name
- WATERWAR (NCT05301049)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Montpellier
Hyponatremia, Syndrome of Inappropriate Antidiuresis
Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis
The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.
- Trial name
- TREASUREx (NCT06821802)
- Testing
- Moltein PURE Protein Powder, Fluid restriction
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- University Hospital, Basel, Switzerland